- Conditions
- Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Interventions
- Atezolizumab, Biopsy Procedure, Biospecimen Collection, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Survey Administration
- Drug · Procedure · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 613 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 338
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 266 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 553–576
of 6,517
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Volunteer
- Interventions
- TR-701 FA 1200 mg, Moxifloxacin 400 mg, TR-701 FA 200 mg plus Placebo, Placebo
- Drug
- Lead sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Bone; Disorder, Development and Growth
- Interventions
- Combined Oral Contraceptive, Transdermal Contraceptive, Contraceptive Vaginal Ring
- Drug
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 18 Years to 30 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
- Conditions
- Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndromes, Neoplasms, Melanoma, Breast Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Renal Cell Carcinoma, Glioblastoma Multiforme, Osteosarcoma, Sarcoma, Thyroid Cancer, Genitourinary
- Interventions
- CC-486, Vidaza
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Iowa City, Iowa + 6 more
- Conditions
- Dental Caries
- Interventions
- Nutrition plus education, Education only
- Behavioral
- Lead sponsor
- UConn Health
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 121 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Farmington, Connecticut
- Conditions
- ADHD, Autism, Bipolar I Disorder, Conduct Disorder, Oppositional Defiant Disorder
- Interventions
- Brexpiprazole
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 4 more
- Conditions
- Advanced Solid Tumors
- Interventions
- TAS-102 with a light tracer dose of [14C]FTD, TAS-102 with a light tracer dose of [14C] TPI, TAS-102 tablets
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Healthy Volunteers
- Interventions
- CTP-543, Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)
- Drug
- Lead sponsor
- Concert Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Hypogonadism, Male
- Interventions
- Testosterone Undecanoate
- Drug
- Lead sponsor
- Clarus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Northbrook, Illinois
- Conditions
- Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
- Interventions
- Asciminib, Nilotinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 568 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 9
- States / cities
- Denver, Colorado • Peoria, Illinois • Saint Paul, Minnesota + 5 more
- Conditions
- Pharmacokinetics, Safety, Food-drug Interaction
- Interventions
- 200 mg resveratrol as JOTROL, 500 mg resveratrol as JOTROL, 700 mg resveratrol as JOTROL, 500 mg resveratrol as JOTROL administered to assess influence of food
- Drug
- Lead sponsor
- Jupiter Orphan Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- EGCG 300 mg + Nintedanib, EGCG 300 mg + Pirfenidone, Placebo 2 capsules + Nintedanib or Pirfenidone, EGCG 600 mg + Nintedanib, EGCG 600 mg + Pirfenidone, Placebo 4 capsules + Nintedanib or Pirfenidone
- Combination Product
- Lead sponsor
- Hal Chapman
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 4 more
- Conditions
- Healthy Aging
- Interventions
- Not listed
- Lead sponsor
- Innovus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 55 Years and older · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Arrhythmias
- Interventions
- azimilide dihydrochloride
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 50
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • La Jolla, California + 43 more
- Conditions
- Care-resistant Behavior, Dementia
- Interventions
- Care-resistant mouth care (MOUTh), Evidence-based mouth care
- Behavioral · Procedure
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 4
- States / cities
- Bellefonte, Pennsylvania • Harrisburg, Pennsylvania • York, Pennsylvania
- Conditions
- Intubation, Intratracheal
- Interventions
- Video Laryngoscopy, Direct Laryngoscopy
- Procedure
- Lead sponsor
- Louisiana State University Health Sciences Center in New Orleans
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Gestational Diabetes
- Interventions
- metformin, Glyburide
- Drug
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 13 Years and older · Female only
- Enrollment
- 149 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2023
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Atovaquone
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 1 Day and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Research Triangle Park, North Carolina
- Conditions
- Estrogen, Cardiovascular Diseases, Microvasculature, Oral Contraceptive Use
- Interventions
- Nω-nitro-L-arginine methyl ester (L-NAME), Acetylcholine, Sodium Nitroprusside
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2031
- U.S. locations
- 1
- States / cities
- Wauwatosa, Wisconsin
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Upadacitinib, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 63 Years
- Enrollment
- 1,014 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 132
- States / cities
- Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 107 more
- Conditions
- Healthy
- Interventions
- Metformin 1000 mg, Vandetanib 800 mg
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- PF-05175157, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Headache, Migraine
- Interventions
- Erenumab, Ethynil Estradiol/Norgestimate Oral Contraceptive
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 4
- States / cities
- Anaheim, California • Cypress, California • Dallas, Texas + 1 more
- Conditions
- Healthy Volunteer
- Interventions
- ABBV-932
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Grayslake, Illinois